Comparative 3D QSAR study on \( \beta_1 \)-, \( \beta_2 \)-, and \( \beta_3 \)-adrenoceptor agonists

P. Senthil Kumar · Prasad V. Bharatam

Received: 16 January 2009 / Accepted: 2 September 2009 / Published online: 31 October 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract  A quantitative structure–activity relationship study of tryptamine-based derivatives of \( \beta_1 \)-, \( \beta_2 \)-, and \( \beta_3 \)-adrenoceptor agonists was conducted using comparative molecular field analysis (CoMFA). Correlation coefficients (cross-validated \( r^2 \)) of 0.578, 0.595, and 0.558 were obtained for the three subtypes, respectively, in three different CoMFA models. All three CoMFA models have different steric and electrostatic contributions, implying different requirements inside the binding cavity. The CoMFA coefficient contour plots of the three models and comparisons among these plots provide clues regarding the main chemical features responsible for the biological activity variations and also result in predictions which correlate very well with the observed biological activity. Based on the analysis, a summary regiospecific description of the requirements for improving \( \beta \)-adrenoceptor subtype selectivity is given.

Keywords  \( \beta \)-Adrenoceptor · G-protein-coupled receptor · 3D-QSAR · Comparative molecular field analysis · Structure–activity relationships · Antiobesity

Introduction

The \( \beta \)-adrenoceptor (\( \beta \)-AR), a member of the G-protein-coupled receptor (GPCR) family, has been the object of several studies aimed at understanding its physiological role and establishing structure–activity relationships for ligands which bind selectively to specific subtypes (Bikker \textit{et al.}, 1998; Lefkowitz, 1998; Wess, 1998; Schoneberg \textit{et al.}, 1999). \( \beta \)-ARs are widely distributed in the human...
body and are found, for example, in the lung, heart, and adipose tissue. The \( \beta \)-AR subtypes mediate several physiological processes including heart rate (Baker, 2005) (\( \beta \)-1), bronchodilatation (Waldeck, 2002; Sears, 2001) (\( \beta \)-2), and lipolysis (Weyer et al., 1999) (\( \beta \)-3). The \( \beta \)-3-AR is involved in various pharmacological and physiological effects including lipolysis, thermogenesis, and relaxation of intestinal smooth muscle (deSouza and Burkey, 2001; Dow, 1997; Igawa et al., 1999). Agents which selectively activate \( \beta \)-3-ARs were proposed to be useful in the treatment of obesity (Weyer et al., 1999), non-insulin-dependent diabetes mellitus, and frequent urination. \( \beta \)-3-AR agonists stimulate the intracellular signaling process to initiate the lipolysis of triglycerides in white adipose tissue. The resulting free fatty acids are processed by uncoupling protein, leading to thermogenesis in brown adipose tissue. The glucose-lowering effect of \( \beta \)-3-AR agonists is mediated through improved peripheral insulin sensitivity. The exact mechanism of the antidiabetic action of this class of compounds is not fully understood. Most of the previously developed \( \beta \)-3-AR compounds have suffered from one or more unacceptable pharmacokinetic or pharmacodynamic problems, including lack of \( \beta \)-3-AR selectivity, tissue specificity, full agonist activity, drug toxicity, and a short plasma half-life (Arch and Wilson, 1996; Himms-Hagen and Danforth, 1996; Danforth and Himms-Hagen, 1997), as a result of which no drug targeted to human the \( \beta \)-3-AR has reached the market so far. Hence attempts to identify clues for \( \beta \)-3-AR selectivity are an urgent requirement.

Many structural classes of \( \beta \)-3-adrenoceptor agonists have been developed; prominent among these classes are the derivatives of arylethanolamine and arylxypropanolamine (Kordik and Reitz, 1999). The following are the important leads in these series: BRL-37344 (Arch et al., 1984), CL-316243 (Bloom et al., 1992), BMS-201620 (Washburn et al., 2004), and L-749372 (Naylor et al., 1998). BRL-37344 was reported to be a selective \( \beta \)-3-AR partial agonist (\( \beta \)-3 EC\(_{50} = 450 \) nM, 23% activation) (Naylor et al., 1998). L-749372 is also a \( \beta \)-3-AR partial agonist (EC\(_{50} = 3.6 \) nM, 33% activation), with 270- and 30-fold selectivity over binding to \( \beta \)-1- and \( \beta \)-2-ARs, respectively (Naylor et al., 1998). The 4-piperidino-benzoic acid derivative CL-316243 was found to be a modestly potent human \( \beta \)-3-AR agonist (EC\(_{50} = 0.22 \) \( \mu \)M) (Sum et al., 1999), and \( N \)-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamide (BMS-201620) a potent \( \beta \)-3 full agonist (\( k_i = 93 \) nM) (Washburn et al., 2004).
A schematic diagram showing the important structural units considered for $\beta_3$-AR agonistic activity in recently reported molecules is given in Scheme 1. The chirality at the hydroxyl center shows that (R) isomers possess the most favorable $\beta_3$ potency and selectivity profile over (S) isomers (Washburn et al., 2001). The aryl group attached to the ethanolamine substructure is important for the biological activity, which can be either phenyl (Nakajima et al., 2005), pyridine (Naylor et al., 1999; Parmee et al., 1999), N-(2-hydroxy-phenyl)methanesulfonamide (Gavai et al., 2001; Hu et al., 2001c) or phenol (Parmee et al., 1998; Weber et al., 1998). $\beta_3$-AR agonist activity of 2,4-thiazolidinedione with several $\beta$-amino alcohols (R1) was reported by Hu et al. (2001b). The amine portion of the ethanolamine group was attached to the central aryl fragment by a two- or three-carbon atom spacer. The central aryl linker fragment was replaced by a benzene (Naylor et al., 1998) or indole moiety (Harada et al., 2003). The central aromatic region was linked to the sulfonamide group, which is understood to be essential for selectivity of $\beta_3$-AR agonistic activity (Uehling et al., 2002). Various research groups introduced acidic functionality on R2 to increase the selectivity for $\beta_3$-AR activity. In addition, they suggested that the steric bulk of the R2 substituent also contributed to the potency and selectivity of $\beta_3$-AR agonists. However, it is thought that introduction of such

Scheme 1 Essential pharmacophore elements present in $\beta_3$-AR agonists, as identified from the reported $\beta_3$-selective arylethanolamine/aryloxypropanolamine derivatives
hydrophilic groups may generally cause low oral bioavailability, partly due to poor absorption (van de Waterbeemd et al., 2001). Numbers of various bulky fragments attached to R2 have been reported. These fragments are long chains with oxadiazolidinedione (Hu et al., 2001d), thiazolidinediones (Hu et al., 2001a), urea (Achsel et al., 2001), triazole (Brockunier et al., 2000), oxazole (Ok et al., 2000), oxadiazole (Feng et al., 2000; Biftu et al., 2000), thiazole (Mathvink et al., 2000), etc.

Molecular modeling studies offer several valuable tools for understanding the interactions of drugs and their receptors on a molecular level (Silverman, 2004). In the case of \( \beta \)-ARs very few molecular modeling studies have appeared to date. This is mainly due to the absence of three-dimensional (3D) information about these receptors. Some bold attempts have been made to computationally model the 3D structure of these targets. Lybrand et al. reported 3D models for agonist and antagonist complexes with \( \beta \)-adrenoceptors using computer modeling techniques (Kontoyianni et al., 1996; Furse and Lybrand, 2003). Saxena and coworkers reported 3D quantitative structure–activity relationship (QSAR) studies on a cyclic ureidobenzenesulfonamides series of molecules using the Apex-3D method (Kashaw et al., 2003; Prathipati and Saxena, 2005), and comparative molecular field analysis (CoMFA) and CoMSIA for different therapeutic areas (Gyanendra et al., 2004; Stuti et al., 2004). Recently, we reported CoMFA studies on a 4-aminomethylpiperidine series of \( \beta \)-AR agonists (Kumar and Bharatam, 2005). In this paper we report comparative studies on the molecular field requirements for a tryptamine based series of molecules toward \( \beta_1 \), \( \beta_2 \), and \( \beta_3 \)-ARs. Kato and coworkers reported the relative biological activities of tryptamine-based agonists toward \( \beta_1 \), \( \beta_2 \), and \( \beta_3 \)-ARs and pointed out that the compounds may be more specific to \( \beta_3 \)-ARs (Mizuno et al., 2004, 2005; Sawa et al., 2004, 2005). A set of 27 molecules from these series was employed in this work to carry out CoMFA studies to identify relative steric and electronic requirements against these three receptors.

Computational details

All molecular modeling techniques and CoMFA studies were performed on a Silicon Graphics Octane2 (R12000) workstation with an IRIX6.5 operating system using the sybyl6.9 molecular modeling software package from Tripos, Inc. (St. Louis, MO, USA, 2002).

Data sets

CoMFA was performed on a series of 27 tryptamine derivatives for which biological activities (EC\(_{50}\) values) are reported with respect to \( \beta_1 \), \( \beta_2 \), and \( \beta_3 \)-ARs (Harada et al., 2003; Mizuno et al., 2004, 2005; Sawa et al., 2004, 2005). The structures and biological activity values of the 27 compounds forming the training set and test set are listed in Table 1; they were assayed in one research laboratory under the same experimental conditions. Only those compounds for which all three biological activities toward \( \beta \)-ARs were available (i.e., \( \beta_1 \), \( \beta_2 \), and \( \beta_3 \)) were selected from the published data. The EC\(_{50}\) is the concentration at which half the maximal
Table 1 Structures of the 27 agonists in the training set and test set and their reported biological activity values

| Molecule | Substituent R | $\beta_1$-AR EC$_{50}$ (nM) | $\beta_2$-AR EC$_{50}$ (nM) | $\beta_3$-AR EC$_{50}$ (nM) |
|----------|---------------|-----------------------------|-----------------------------|-----------------------------|
| 1$^a$    | –             | 1.9                         | 25                          | 5.4                         |
| 2$^b$    | –             | 47                          | 330                         | 220                         |
| 3        | Me            | 0.13                        | 5.2                         | 0.36                        |
| 4        | CH$_2$COOH    | 6.4                         | 13                          | 0.062                       |
| 5        | –             | 1700                        | 290                         | 21.0                        |
| 6        | H             | 21                          | 66                          | 0.88                        |
| 7        | OMe           | 6.6                         | 29                          | 0.55                        |
| 8        | OCH$_2$Ph     | 6.6                         | 54                          | 0.76                        |
| 9        | OCH$_2$CONEt$_2$ | 6.8                        | 19                          | 1.30                        |
| 10       | OCH$_2$COOH   | 19                          | 180                         | 1.70                        |
| 11       | OSO$_2$Me     | 18                          | 44                          | 0.21                        |
Table 1 continued

| Molecule | Substituent R | $\beta_1$-AR EC$_{50}$ (nM) | $\beta_2$-AR EC$_{50}$ (nM) | $\beta_3$-AR EC$_{50}$ (nM) |
|----------|---------------|-----------------------------|-----------------------------|-----------------------------|
| 12       | OSO$_2$-$n$-butyl | 7.3                         | 26                          | 0.59                        |
| 13       | OSO$_2$-$n$-octyl | 5.6                         | 20                          | 0.28                        |
| 14       | OSO$_2$-iPr      | 6.2                         | 40                          | 0.51                        |
| 15       | OSO$_2$Ph       | 3.1                         | 72                          | 0.87                        |
| 16       | OSO$_2$-3-pyridyl | 1.3                         | 22                          | 0.26                        |
| 17       | OSO$_2$-2-thienyl | 1.2                         | 49                          | 0.64                        |
| 18       | OSO$_2$-2-CO$_2$Et | 7.2                         | 58                          | 1.20                        |
| 19       | –               | 13                          | 26                          | 0.47                        |
| 20       | –               | 19                          | 13                          | 0.54                        |
| 21       | –               | 69                          | 120                         | 160                         |
| 22       |                | 10                          | 170                         | 1.2                         |
| 23       |                | 36                          | 160                         | 36                          |
| 24       |                | 9.6                         | 45                          | 10                          |
**Table 1 continued**

| Molecule | Substituent R | $\beta_1$-AR EC$_{50}$ (nM) | $\beta_2$-AR EC$_{50}$ (nM) | $\beta_3$-AR EC$_{50}$ (nM) |
|----------|---------------|-----------------------------|-----------------------------|-----------------------------|
| 25       |               | 7.6                         | 44                          | 2.9                         |
|          | ![](image)    |                             |                             |                             |
| 26       | –             | 22                          | 32                          | 4.4                         |
| 27       | –             | 44                          | 53                          | 1.0                         |

*a* Configuration R at hydroxyl and methyl center

*b* Configuration S at hydroxyl and R at methyl center
response of the compound was observed. Biological activities are reported with EC50 values ranging from 0.13 to 1700, 5.2 to 330, and 0.062 to 220 nM for human β1-, β2-, and β3-ARs, respectively. The biological activities in the training set were converted to pEC50 values of the agonists, which are the negative logarithms of the molar concentration value, and used as dependent variables in the CoMFA.

Structure generation and alignment

Compounds in the training set were generated from the x-ray crystal structures or by modification of the crystal structure of similar compounds using the SYBYL BUILD option (Tripos Inc. 2002). Conformation of compound 4 in the training set was taken from the x-ray crystal structure reported on the same molecule as given in the Cambridge Crystallographic Structural Database Centre (CCDC No. 203813) (Harada et al., 2003). All remaining compounds were built from the crystal structure of compound 4. Energy minimization was performed using the Tripos force field with a distance-dependent dielectric and conjugate gradient algorithm with a convergence criterion of 0.005 kcal/mol. Partial atomic charges were calculated using the Gasteiger–Huckel method (Gasteiger and Marsili, 1980). CoMFA studies require that the 3D structures of the molecules to be analyzed be aligned according to a suitable conformational template, which is assumed to be a “bioactive” conformation. Molecular alignment was carried out using the SYBYL “fit-atom” alignment function (Tripos Inc. 2002). The crystal structure of compound 4 was used as the alignment template. Figure 1 shows the 3D alignment of 27 molecules according to the alignment scheme in Fig. 2.

CoMFA study

The CoMFA descriptors were used as independent variables, and pEC50 values where used as dependent variables, in partial least squares (PLS) (Wold et al., 1984) regression analysis to derive 3D QSAR models. The steric (Lennard-Jones) and electrostatic (Coulomb) CoMFA fields were calculated using an sp3 carbon as the steric probe atom and a +1 charge for the electrostatic probe. A grid spacing of 2 Å and a distance-dependent dielectric constant were chosen. The cutoff value for both steric and electrostatic interactions was set to 30 kcal/mol.

![Fig. 1](image) The 3D alignment of the 27 molecules is shown by capped sticks without hydrogens
Partial least squares analysis

PLS regression analyses were performed using cross-validation to evaluate the predictive ability of the CoMFA models. Initial PLS regression analyses were performed in conjunction with the cross-validation (leave-one-out method) option to obtain the optimal number of components to be used in the subsequent analysis of the dataset. All the leave-one-out cross-validated PLS analyses were performed with a column filter value of 2.0 kcal/mol to improve the signal-to-noise ratio by omitting those lattice points whose energy variation was below this threshold value. The final PLS regression analysis with 10 bootstrap groups and the optimal number of components was performed on the complete dataset. The optimal number of components was determined by selecting the smallest PRESS value. Usually this value corresponds to the highest cross-validated \( r^2_{cv} \) value. The \( r^2_{cv} \) was calculated using the formula

\[
r^2_{cv} = 1 - \frac{\sum (Y_{\text{predicted}} - Y_{\text{observed}})^2}{\sum (Y_{\text{observed}} - Y_{\text{mean}})^2}
\]

where \( Y_{\text{predicted}} \), \( Y_{\text{observed}} \), and \( Y_{\text{mean}} \) are the predicted, actual, and mean values of the target property (pEC50), respectively. The number of components obtained from the cross-validated analysis was subsequently used to derive the final QSAR models. In addition to \( r^2_{cv} \), the corresponding PRESS [PRESS = \( \sum (Y_{\text{predicted}} - Y_{\text{observed}})^2 \)], the number of components, the nonconventional correlation coefficient \( r^2_{ncv} \), and its standard errors were also computed.

Test sets

To test the predictive power of the CoMFA model, seven agonists from the \( \beta_1 \)- and \( \beta_2 \)-AR subtypes and five agonists from the \( \beta_3 \)-AR subtype were selected as the test set (Table 2). The agonists in the test set were chosen by random sampling of biological activity. The conformation, minimization, and alignment of these agonists in the test set were obtained by the same protocol as that described for the agonists in the training set used. All predicted activities for test-set molecules were calculated using the optimized CoMFA model. The results of the non-cross-validated calibration model on the test sets are summarized in Table 3.
Predictive $r^2$ values

The predictive $r^2 (r^2_{\text{pre}})$ was based only on molecules not included in the training set and is defined as explained by Marshall and co-workers (Oprea et al., 1994; Waller et al., 1993).
where SD is the sum of the squared deviations between the biological activities of molecules in the test set and the mean activity of the training-set molecules, and PRESS is the sum of the squared deviations between predicted and actual biological activity values for every molecule in the test set. This is analogous to Cramer’s definition: whenever PRESS is larger than SD, this results in a negative value reflecting complete lack of predictive ability of the training set for the molecules included in the test set (Cramer et al., 1988).

### Results

**CoMFA of the β1-adrenoceptor**

PLS analysis was used in combination with cross-validation to obtain the optimal number of components to be used in the subsequent non-cross-validation analysis. PLS analysis based on least squares fit gave a correlation with a cross-validated $r_{cv}^2$ of 0.578, with the maximum number of components set equal to five. The non-cross-validated PLS analysis was repeated with the five components, giving an $r_{ncv}^2$ of 0.993. To obtain statistical confidence limits, the non-cross-validated analysis was repeated with 10 bootstrap groups, which yielded an $r_{pre}^2$ of 0.96 (five components, SEE = 0.027, std dev = 0.003, steric contribution = 0.558, and electrostatic contribution = 0.442). These parameters are listed in Table 3. The above satisfactory cross-validated correlation coefficient indicates that the CoMFA model is highly reliable. The high bootstrapped $r^2$ value and low standard deviation suggest a high degree of confidence in the analysis. The calculated biological activities obtained from the analysis are plotted versus the actual values in Fig. 3a. Compounds 9, 10, 11, 15, 18, 23, and 24 (test set) were used to evaluate the

### Table 3: Statistical parameters associated with the three CoMFA models β1, β2, and β3

| Parameter | $β_1$ | $β_2$ | $β_3$ |
|-----------|-------|-------|-------|
| $N$       | 17    | 17    | 17    |
| No. components | 5     | 5     | 6     |
| $r_{cv}^2$ | 0.578 | 0.595 | 0.558 |
| $r_{ncv}^2$ | 0.993 | 0.976 | 0.995 |
| $F_{test}$ | 305.3 | 90.5  | 310.7 |
| $r_{bs}^2$ | 0.996 | 0.997 | 0.999 |
| $r_{pre}^2$ | 0.847 | 0.607 | 0.758 |
| Std dev (bs) | 0.003 | 0.003 | 0.001 |
| SEE        | 0.027 | 0.023 | 0.033 |
| Steric field contribution | 0.558 | 0.394 | 0.401 |
| Electrostatic field contribution | 0.442 | 0.606 | 0.599 |

Note: $N$, number of compounds; $r_{cv}^2$, cross-validation by leave-one-out method; $r_{ncv}^2$, non-cross-validation; $r_{bs}^2$, 10 bootstrapping runs; $r_{pre}^2$, predictive $r^2$; SEE, standard error of estimate.
predictive power of this CoMFA model. As in the calibration step, a good predictive ability, with an $r_{\text{pre}}^2 = 0.847$, for the compounds in the test set was obtained. Table 2 reports that the predicted values fall close to the observed biological activity value, deviating by less than one logarithmic unit.

The $\beta_1$ CoMFA steric and electrostatic fields from the final non-cross-validated analysis are plotted as three-dimensional color contour maps in Figs. 4a and 5a, respectively, along with the reference compound, 16. These contour maps indicate the regions where differences in molecular fields are associated with differences in biological activity. Green contours indicate regions in which increasing steric bulk is tolerable, and yellow contours indicate regions in which the steric bulk decreases the activity. In the $\beta_1$ model the steric contours show that the substituents attached to the ring of the arylethanolamine group are placed in sterically unfavorable regions. Of the four yellow contours near the arylethanolamine group three of them
are below the local plane of the reference compound and one is above the five-membered ring of the reference compound. These yellow regions indicate that additional steric interactions in these regions would lead to decreased biological activity. The above observations indicate that for good $\beta_1$-agonistic activity there should be only very small groups or no substituents on the aryl ring of arylethanolamine. These can account for a limiting size and shape for the substituents that would be effective for tight binding to the receptor. A big yellow contour above the indole ring indicates that any substituents on the nitrogen of the

**Fig. 4** CoMFA steric STDEV*COEFF contour plots of the tryptamine-based derivative training set generated for the $\beta_1$ (a), $\beta_2$ (b), and $\beta_3$ (c) models. Compounds 16 (a, c) and 20 (b) are shown inside the field
Indole ring would greatly reduce the biological activity, suggesting limited bulk tolerance. The small green region at the C7 position of the indole nucleus indicates that increases in the steric bulk at this position are marginally favorable for $\beta_1$-AR activity. The electrostatic contour map (Fig. 5a) of the CoMFA model shows a small blue contour near the SO$_2$ group attached to arylethanolamine and red contours near the C7 substituents on the indole ring. This indicates that a reduction in the electronegativity near the SO$_2$ group and increasing electronegativity at the C7 position of indole should lead to increased $\beta_1$ activity.

**Fig. 5** CoMFA electrostatic STDEV*COEFF contour plots of the tryptamine-based derivative training set generated for the $\beta_1$ (a), $\beta_2$ (b), and $\beta_3$ (c) models. Compounds 16 (a, c) and 20 (b) are shown inside the field.
CoMFA of the $\beta_2$-adrenoceptor

The $\beta_2$ CoMFA analysis based on the fit atom alignment yielded good cross-validated ($r^2_{cv} = 0.595$) and conventional $r^2 (r^2 = 0.976, F - test$ value $= 90.518$), with the optional number of components found to be five. The steric and electrostatic fields contribute to the QSAR equation by 39.4% and 60.6%, respectively. A high bootstrapped (10 sampling) $r^2_{bs}$ value of 0.997 (SEE $= 0.023$, std dev $= 0.003$) was found. A plot of actual versus calculated biological activity obtained from the analysis is given in Fig. 3b. Compounds 10, 12, 14, 16, 17, 21, and 27 (test set) were used to evaluate the predictive power of this CoMFA model. A good predictive ability, with an $r^2_{pre} = 0.607$, for the compounds in the test set was obtained in this calibration step. Table 2 reports that the predicted values fall close to the observed biological activity value, deviating by less than one logarithmic unit.

The $\beta_2$ CoMFA steric and electrostatic fields from the final non-cross-validated analysis are plotted in Figs. 4b and 5b respectively. The most active compound, 20, was treated as the reference molecule. The graphical interpretation of the field contribution of the steric contour map is shown in Fig. 4b. The steric contour map shows three yellow regions surrounding the phenyl unit in the NHSO$_2$Ph group, and a small green at the para position on the same ring. This indicates that it is preferable to reduce the steric bulk due to the Ph group. The presence of a simple thiophen ring, as in many other molecules in this series, is preferable for $\beta_2$ activity. A very large yellow contour is noted near the C7 of the indole ring in Fig. 4b, indicating that the steric bulk should be reduced for improved $\beta_2$ activity. The CoMFA electrostatic contour map displays a large blue region surrounding the SO$_2$Ph group and two small red regions in close proximity, suggesting that a strong reduction in the electronegative groups is preferred in this region. There are two small blue regions and one small red region at the C7 of the indole ring of the reference compound. The distribution range of blue is higher than that of red, indicating that electropositive groups in this region are very important for the $\beta_2$ biological activity.

CoMFA of the $\beta_3$-adrenoceptor

The $\beta_3$ CoMFA analysis based on the fit atom alignment yielded acceptable cross-validated ($r^2_{cv} = 0.558$) and conventional results ($r^2 = 0.995, F - test$ value $= 310.717$), with the optimal number of components found to be six. In this model, steric and electrostatic fields contribute to the QSAR equation by 40.1% and 59.9%, respectively. The high bootstrapped (10 sampling) $r^2_{bs}$ value of 0.999 (SEE $= 0.033$, std dev $= 0.001$) was found. Compounds 8, 10, 14, 18, and 20 (test set) were used to evaluate the predictive power of this CoMFA model. The predicted versus the actual values of biological activities obtained from the analysis are plotted in Fig. 3c. The $\beta_3$ CoMFA model shows a very good predictive ability, with $r^2_{pre} = 0.758$ for the compounds in the test set, as obtained for the calibration steps. Table 2 shows that the predicted values fall close to the observed biological activity value, deviating by less than one logarithmic unit.
The steric and electrostatic contour maps obtained from the $\beta_3$ CoMFA model are shown in Figs. 4c and 5c, respectively, along with compound 16. In Fig. 4c, the steric contour map shows a large green region around the substituent on the aryl ring, indicating the presence of a $\beta_3$-AR binding pocket which can accommodate bulky substituents of large size, such as isopropyl and t-butyl. The presence of a bulky substituent at the indole ring decreases activity because of steric hindrance, as indicated by the yellow contour. Figure 5c shows a huge blue contour near the thiophen ring, indicating that decreasing electronegative character/increasing electropositive character is an important consideration in this region for improved $\beta_3$-agonistic activity.

**Discussion**

Three different 3D QSAR models have been developed using the CoMFA methodology for tryptamine-based analogues of $\beta$-AR agonists. This is a first attempt to describe quantitatively the hypothetical receptor binding site of multiple subtypes of $\beta$-ARs. Comparison of the three CoMFA models helps in understanding $\beta$-AR selectivity. The main steric and electrostatic interactions on the binding cavity of $\beta_1$-, $\beta_2$-, and $\beta_3$-ARs are demonstrated in Scheme 2. The 3D QSAR CoMFA of these $\beta$-AR subtypes led to the following considerations:

The $\beta_2$ and $\beta_3$ CoMFA models show similarities in their overall steric and electrostatic contributions. In the $\beta_1$ CoMFA model the steric contribution is larger, whereas in the $\beta_2$ and $\beta_3$ CoMFA models the electrostatic contribution is larger (see Table 3). Detailed CoMFA contour map analysis shows that decreasing steric bulk is preferable for increased $\beta_1$ and $\beta_2$ activity near the sulfonamide unit. On the other hand, increasing steric bulk is preferable for the $\beta_3$-AR activity near the phenyl

**Scheme 2** Proposed hypothetical receptor model of $\beta$-ARS binding site
sulfonamide unit. Strong yellow contours are observed near the C7 unit of the indole ring in all three CoMFA models, indicating that smaller functional units are preferable in this region. From this information, it may be inferred that the active site of β3-AR can accommodate large substituents on the left-hand side for tight binding. Thus, β3-selectivity of this series of compounds can be brought about by employing large groups on the phenyl unit of phenyl sulfonamide in 16. It is preferable to reduce the steric effects on the C7 of the indole ring in 16 for all (β1, β2, β3) activities. Figure 5 shows that there are distinguishable differences in the electrostatic fields of β1, β2, and β3 CoMFA models. In all the models, increasing electropositive character is preferred near the SO₂Ar unit in 16, the influence of which increased in the order β1 < β2 < β3. This requirement is very strong for β3-agonistic activity. Thus, large substituents with a strong electropositive character on the Ar unit of SO₂Ar are required for β3 specificity. On the other hand, electrostatic factors appear to be optimum for β3 activity on the right-hand side of Scheme 2. However, increasing electronegative substituents are favorable for β1 activity and increasing electropositive character is favorable for β2 selectivity. These factors are summarized in Scheme 2. In summary, the absence of information on the experimental binding mode of these agonists toward their β-ARs, the binding mode information obtained for the comparative 3D QSAR studies shall be helpful in modulating the tryptamine series of molecules for selectivity against β1, β2, and β3 activities.

**Conclusion**

In this paper, we have established CoMFA models for a series of tryptamine-based analogues for various subtypes of β-AR agonists, i.e., β₁-, β₂-, and β₃-AR agonists. Three different 3D QSAR models have been established for β₁-AR, β₂-AR, and β₃-AR agonistic activities in a series of tryptamine molecules using the CoMFA method. All three models show satisfactory statistical significance values $r^2_{cv}$ (0.578, 0.575, 0.558), SEE (0.027, 0.023, 0.033), etc. Comparative study of the steric and electrostatic contour maps provided clues to the chemical modulations required for improving specificity. For β₃-specificity, for example, increased steric bulk and increased electropositive character are required on the aryl group of the SO₂Ar unit in this series of molecules. Based on the present 3D QSAR CoMFA studies, a hypothetical receptor model of these agonists with the β₃-AR is proposed (see Scheme 2). Since information related to the 3D structure of the active site of the three β-ARs is not available, information provided in this article in the form of molecular field requirement shall be of help in designing selective β₃-AR agonists.

**Acknowledgment**  P.S.K. thanks the Council of Scientific and Industrial Research (CSIR), New Delhi, for financial support through a Senior Research Fellowship.

**Open Access**  This article is distributed under the terms of the Creative Commons Attribution Non-commercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
References

Arch JRS, Wilson S (1996) Prospects for beta-3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes Relat Metab Disord 20:191–199

Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163–165

Ashwell MA, Solvibile WR Jr, Han S, Largis E, Mulvey R, Tillett J (2001) 4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor. Bioorg Med Chem Lett 11:3123–3127

Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 41:2911–2927

Biftu T, Feng DD, Liang GB, Kuo H, Qian X, Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Forrest MJ, Hom GJ, MacIntyre DE, Stearns RA, Strader CD, Wyvrrat MJ, Fisher MH, Weber AE (2000) Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents. Bioorg Med Chem Lett 10:1431–1434

Bikker JA, Trump-Kallmeyer S, Humblet C (1998) G-Protein coupled receptors: models, mutagenesis, and drug design. J Med Chem 41:2911–2927

Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, Dolan JA, Claus TH (1992) Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316, 243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 35:3081–3084

Brockunier LL, Parmee ER, Ok HO, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvrrat MJ, Fisher MH, Weber AE (2000) Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides. Bioorg Med Chem Lett 10:2111–2114

Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967

Danforth E Jr, Himms-Hagen J (1997) Obesity and diabetes and the beta-3 adrenergic receptor. Eur J Endocrinol 136:362–365

deSouza CJ, Burkey BF (2001) Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des 7:1433–1449

Dow RL (1997) Beta3-adrenergic agonists: potential therapeutics for obesity. Exp Opin Invest Drugs 6:1811–1825

Feng DD, Biftu T, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvrrat MJ, Fisher MH, Weber AE (2000) Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist. Bioorg Med Chem Lett 10:1427–1429

Furse KE, Lybrand TP (2003) Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J Med Chem 46:4450–4462

Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219–3228

Gavai AV, Sher PM, Mikkilineni AB, Pos KM, McCann PJ, Girotra RN, Fisher LG, Wu G, Bednarz MS, Mathur A, Wang TC, Sun CQ, Slusarchyik DA, Skwish S, Allen GT, Hillyer DE, Frohlich BH, Abbo-Ottefi BE, Cap M, Waldran TL, George RJ, Tesfamariam B, Harper TW, Ciosek CP Jr, Young DA, Dickinson KE, Seymour AA, Arbeeny CM, Washburn WN (2001) BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor. Bioorg Med Chem Lett 11:3041–3044

Gyanendra P, Sushil KK, Anil KS (2004) CoMFA, Advanced CoMFA and CoMSIA studies on the oxazainazole substituted z-isopropoxy phenylpropionic acids for PPARz agonistic activity. Med Chem Res 13:677–686

Harada H, Hikokawa Y, Suzuki K, Hiyama Y, Oue M, Kawashima H, Yoshida N, Furutani Y, Kato S (2003) Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines. Bioorg Med Chem Lett 13:1301–1305

Himms-Hagen J, Danforth E Jr (1996) The potential role of beta-3 adrenoceptor agonists in the treatment of obesity and diabetes. Curr Opin Endocrinol Diabetes 3:59–65
Hu B, Ellingboe J, Gunawan I, Han S, Largis E, Li Z, Malamas M, Mulvey R, Oliphant A, Sum FW, Tillett J, Wong V (2001a) 2,4-Thiazolidinediones as potent and selective human beta3 agonists. Bioorg Med Chem Lett 11:757–760

Hu B, Ellingboe J, Han S, Largis E, Lim K, Malamas M, Mulvey R, Niu C, Oliphant A, Pelletier J, Singanallorre T, Sum FW, Tillett J, Wong V (2001b) Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human beta(3) agonists. J Med Chem 44:1456–1466

Hu B, Malamas M, Ellingboe J, Largis E, Han S, Mulvey R, Tillett J (2001c) New oxadiazolidinedione derivatives as potent and selective human beta3 agonists. J Med Chem 44:1456–1466

Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819–825

Kashaw SK, Rathi L, Mishra P, Saxena AK (2003) Development of 3D-QSAR models in cyclic ureidobenzensulphonamides: human beta3-adrenergic receptor agonist. Bioorg Med Chem Lett 13:2481–2484

Kontoyianni M, DeWeese C, Penzotti JE, Lybrand TP (1996) Three-dimensional models for agonist and antagonist complexes with beta 2 adrenergic receptor. J Med Chem 39:4406–4420

Kordik CP, Reitz AB (1999) Pharmacological treatment of obesity: therapeutic strategies. J Med Chem 42:181–201

Kumar PS, Bharatam PV (2005) CoMFA study on selective human b3-adrenoreceptor agonists. Arkivoc xiii:67–79

Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273:18677–18680

Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvrett MJ, Fisher MH, Weber AE (2000) Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzene-sulfonamide pharmacophore. Bioorg Med Chem Lett 10:1971–1973

Mizuno K, Sawa M, Harada H, Tateishi H, Oue M, Tsujiuchi H, Furutani Y, Kato S (2004) Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring. Bioorg Med Chem Lett 14:5959–5962

Mizuno K, Sawa M, Harada H, Taoka I, Yamashita H, Oue M, Tsujiuchi H, Arai Y, Suzuki S, Furutani Y, Kato S (2005) Discovery of 1, 7-cyclized indoles as a new class of potent and highly selective human beta3-adrenergic receptor agonists with high cell permeability. Bioorg Med Chem Lett 13:855–868

Nakajima Y, Hamashima H, Washizuka K, Tomishima Y, Ohtake H, Imamura E, Miura T, Kayakiri H, Kato M (2005) Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist. Bioorg Med Chem Lett 15:251–254

Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvrett MJ, Fisher MH, Weber AE (1998) 3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists. Bioorg Med Chem Lett 8:3087–3092

Naylor EM, Parmee ER, Colandrea VJ, Perkins L, Brockunier L, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvrett MJ, Fisher MH, Weber AE (1999) Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzensulfonylamides. Bioorg Med Chem Lett 9:755–758

Ok HO, Reigle LB, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang P, Wyvrett MJ, Fisher MH, Weber AE (2000) Substituted oxazole benzensulfonylamides as potent human beta3 adrenergic receptor agonists. Bioorg Med Chem Lett 10:1531–1534

Oprea TI, Waller CL, Marshall GR (1994) Three-dimensional quantitative structure–activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J Med Chem 37:2206–2215

Parmee ER, Ok HO, Candelore MR, Tota L, Deng L, Strader CD, Wyvrett MJ, Fisher MH, Weber AE (1998) Discovery of L-7,557, 507: a subnanomolar human beta 3 adrenergic receptor agonist. Bioorg Med Chem Lett 8:1107–1112
Parmee ER, Naylor EM, Perkins L, Colandrea VI, Ok HO, Candelore MR, Cascieri MA, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE (1999) Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides. Bioorg Med Chem Lett 9:749–754

Prathipati P, Saxena AK (2005) Characterization of beta3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for beta3 adrenergic receptor agonism. J Comput Aided Mol Des 19:93–110

Sawa M, Tateishi H, Mizuno K, Harada H, Oue M, Tsujiuchi H, Furutani Y, Kato S (2004) Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives. Bioorg Med Chem Lett 14:5963–5966

Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S (2005) Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moieties. Bioorg Med Chem Lett 15:1061–1064

Schoneberg T, Schultz G, Gudermann T (1999) Structural basis of G protein-coupled receptor function. Mol Cell Endocrinol 151:181–193

Sears MR (2001) The evolution of beta2-agonists. Respir Med 95 (Suppl B):S2–S6

Silverman RB (ed) (2004) The organic chemistry of drug design and drug action. Elsevier, London

Stuti G, Philip P, Mridula S, Anil KS (2004) CoMFA and CoMSIA studies on a set of benzyl piperazines, piperidines, pyrazinopipridinoides, pyrazinoisquinolines and semi rigid analogs of diphenhydramine. Med Chem Res 13:746–757

Sum FW, Gilbert A, Venkatesan AM, Lim K, Wong V, O’Dell M, Francisco G, Chen Z, Grosu G, Baker J, Ellingboe J, Malamas M, Gunawan I, Primeau J, Largis E, Steiner K (1999) Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes. Bioorg Med Chem Lett 9:1921–1926

Uehling DE, Donaldson KH, Deaton DN, Hyman CE, Sugg EE, Barrett DG, Hughes RG, Reitter B, Adkson KK, Lancaster ME, Lee F, Hart R, Paulik MA, Sherman BW, True T, Cowan C (2002) Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonyleurea carboxylic acid isosteres. J Med Chem 45:567–583

d van De Waterbeemd H, Smith DA, Beaumont K, Walker DK (2001) Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313–1333

Waldeck B (2002) Beta-adrenoceptor agonists and asthma—100 years of development. Eur J Pharmacol 445:1–12

Waller CL, OpreaTI Giolitti A, Marshall GR (1993) Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. J Med Chem 36:4152–4160

Washburn WN, Sher PM, Poss KM, Girotra RN, McCann PJ, Gavai AV, Mikkilineni AB, Mathur A, Cheng P, Dejneca TC, Sun CQ, Wang TC, Harper TW, Russell AD, Slusarchyk DA, Skwish S, Allen GT, Hillyer DE, Frohlich BH, Abbo-Bofei BE, Cap M, Waldron TL, George RJ, Tesfamariam B, Ciosek CP Jr, Ryono D, Young DS, Dickinson KE, Seymour AA, Arbeeny CM, Gregg RE (2001) Beta 3 agonists. Part 1: Evolution from inception to BMS-194449. Bioorg Med Chem Lett 1:3035–3039

Washburn WN, Sun CQ, Bisacchi G, Wu G, Cheng PT, Sher PM, Ryono D, Gavai AV, Poss K, Girotra RN, McCann PJ, Mikkilineni AB, Dejneca TC, Wang TC, Merchant Z, Morella M, Arbeeny CM, Harper TW, Slusarchyk DA, Skwish S, Russell AD, Allen GT, Tesfamariam B, Frohlich BH, Abbo-Offei BE, Cap M, Waldron TL, George RJ, Young D, Dickinson KE, Seymour AA (2004) BMS-201620: a selective beta 3 agonist. Bioorg Med Chem Lett 14:3525–3529

Weber AE, Mathvink RJ, Perkins L, Hutchins JE, Candelore MR, Tota L, Strader CD, Wyvratt MJ, Fisher MH (1998) Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor. Bioorg Med Chem Lett 8:1101–1106

Wess J (1998) Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80:231–264

Weyer C, Gautier JF, Danforth E Jr (1999) Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes—an update. Diabetes Metab 25:11–21

Wold S, Ruhe A, Wold H, Dunn WJ (1984) The collinearity problem in linear regression the partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput 5:735–743